Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through its proprietary XR-17 platform technology. Its solubility-enhancing technology has received validation through a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancer indications. Apealea’s initial indication is ovarian cancer (approved in Europe) and Elevar plans to complete two additional studies before filing an NDA in the US. Oasmia is also working on additional nanoparticle formulations, including docetaxel micellar (Phase Ib prostate cancer), and the development of innovative drugs (preclinical stage). Oasmia has an animal health pipeline with two clinical stage assets, Paccal Vet and Doxophos Vet.
In this interview, CEO Dr Francois Martelet gives an overview of the company, its lead asset Apealea and its proprietary XR-17 platform. He discusses Oasmia’s renewed strategic focus and the pathway to approval for Apealea in the US. He also discusses the growing clinical pipeline and the key catalysts to look out for over the next 12 months.